Design of Novel Acute Myeloid Leukemia Therapeutic Targeting of CNOT3

CNOT3 新型急性髓系白血病治疗靶点的设计

• 批准号: 486293
• 负责人: Gomes Renessa
• 金额: $ 1.27万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-12-01 至 2023-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=486293&lang=en
• 关键词: Acute Myeloid Leukemia; Cnot3; Deadenylation; Degradation Tag; Proteolysis Targeting Chimeric; Targeted Protein Degradation; Therapeutic Design

Acute myeloid leukemia (AML) is an aggressive type of blood cancer characterized by accumulation of immature blood cells. Chemotherapy has remained the standard of care for AML since the 1970s yet 5-year survival rates are <35% in young adults and <15% in

急性髓系白血病 (AML) 是一种侵袭性血癌，其特征是未成熟血细胞积聚。自 20 世纪 70 年代以来，化疗一直是 AML 的标准治疗方法，但年轻人的 5 年生存率<35%，成年患者的 5 年生存率<15%。